Mechanism of rapid elimination of lysophosphatidic acid and related lipids from the circulation of mice

Journal of Lipid Research

Volumn 54, Issue 10, 2013, Pages 2775-2784

  Salous, Abdel K ^a   Panchatcharam, Manikandan ^a   Sunkara, Manjula ^a   Mueller, Paul ^a   Dong, Anping ^a   Wang, Yuhuan ^b   Graf, Gregory A ^b   Smyth, Susan S ^a,c   Morris, Andrew J ^a,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c LEXINGTON VA MEDICAL CENTER   (United States)

Author keywords

Autotaxin; Lipid phosphate phosphatase; Mass spectrometry; Transcellular uptake

Indexed keywords

LYSOPHOSPHATIDIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL FRACTIONATION; CELL TRANSPORT; CONTROLLED STUDY; DEPHOSPHORYLATION; ELIMINATION REACTION; ENZYME DEGRADATION; FEMALE; HUMAN; HUMAN CELL; LIPID METABOLISM; LIVER CELL; LIVER CIRCULATION; LIVER METABOLISM; MALE; MOUSE; NONHUMAN; PORTAL VEIN; PRIMARY CELL CULTURE; PRIORITY JOURNAL;

AUTOTAXIN; LIPID PHOSPHATE PHOSPHATASE; MASS SPECTROMETRY; TRANSCELLULAR UPTAKE;

ANIMALS; BENZOXAZOLES; CELLS, CULTURED; HALF-LIFE; HEPATOCYTES; LIPID METABOLISM; LIVER; LYSOPHOSPHOLIPIDS; MALE; MICE; MICE, INBRED C57BL; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

EID: 84884147849     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M039685     Document Type: Article

References (39)

1. Tigyi, G. 2013. New trends in lysophospholipid research. Biochim. Biophys. Acta. 1831: 1.
2. Morris, A. J., and S. S. Smyth. 2013. Lysophosphatidic acid and cardiovascular disease: seeing is believing. J. Lipid Res. 54: 1153-1155.
3. Morris, A. J., S. Selim, A. Salous, and S. S. Smyth. 2009. Blood relatives: dynamic regulation of bioactive lysophosphatidic acid and sphingosine-1-phosphate metabolism in the circulation. Trends Cardiovasc. Med. 19: 135-140.
4. Haseruck, N., W. Erl, D. Pandey, G. Tigyi, P. Ohlmann, C. Ravanat, C. Gachet, and W. Siess. 2004. The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: involvement of P2Y1 and P2Y12 receptors. Blood. 103: 2585-2592.
5. Panchatcharam, M., S. Miriyala, F. Yang, M. Rojas, C. End, C. Vallant, A. Dong, K. Lynch, J. Chun, A. J. Morris, et al. 2008. Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure. Circ. Res. 103: 662-670.
6. Panchatcharam, M., S. Miriyala, A. Salous, J. Wheeler, A. Dong, P. Mueller, M. Sunkara, D. Escalante-Alcalde, A. J. Morris, and S. S. Smyth. 2013. Lipid phosphate phosphatase 3 negatively regulates smooth muscle cell phenotypic modulation to limit intimal hyperplasia. Arterioscler. Thromb. Vasc. Biol. 33: 52-59.
7. Cheng, Y., N. Makarova, R. Tsukahara, H. Guo, E. Shuyu, P. Farrar, L. Balazs, C. Zhang, and G. Tigyi. 2009. Lysophosphatidic acidinduced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR. Cell. Signal. 21: 1874-1884.
8. Mehta, N. N. 2011. A genome-wide association study in Europeans and South Asians identifies 5 new loci for coronary artery disease. Circ Cardiovasc Genet. 4: 465-466.
9. Umezu-Goto, M., Y. Kishi, A. Taira, K. Hama, N. Dohmae, K. Takio, T. Yamori, G. B. Mills, K. Inoue, J. Aoki, et al. 2002. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell Biol. 158: 227-233.
10. Tanaka, M., S. Okudaira, Y. Kishi, R. Ohkawa, S. Iseki, M. Ota, S. Noji, Y. Yatomi, J. Aoki, and H. Arai. 2006. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J. Biol. Chem. 281: 25822-25830.
11. Albers, H. M., A. Dong, L. A. van Meeteren, D. A. Egan, M. Sunkara, E. W. van Tilburg, K. Schuurman, O. van Tellingen, A. J. Morris, S. S. Smyth, et al. 2010. Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc. Natl. Acad. Sci. USA. 107: 7257-7262.
12. Gierse, J., A. Thorarensen, K. Beltey, E. Bradshaw-Pierce, L. Cortes- Burgos, T. Hall, A. Johnston, M. Murphy, O. Nemirovskiy, S. Ogawa, et al. 2010. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. J. Pharmacol. Exp. Ther. 334: 310-317.
13. Tomsig, J. L., A. H. Snyder, E. V. Berdyshev, A. Skobeleva, C. Mataya, V. Natarajan, D. N. Brindley, and K. R. Lynch. 2009. Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo. Biochem. J. 419: 611-618.
14. Venkataraman, K., Y. M. Lee, J. Michaud, S. Thangada, Y. Ai, H. L. Bonkovsky, N. S. Parikh, C. Habrukowich, and T. Hla. 2008. Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ. Res. 102: 669-676.
15. Coy, D. J., C. R. Wooton-Kee, B. Yan, N. Sabeva, K. Su, G. Graf, and M. Vore. 2010. ABCG5/ABCG8-independent biliary cholesterol excretion in lactating rats. Am. J. Physiol. Gastrointest. Liver Physiol. 299: G228 - G235.
16. Seglen, P. O. 1976. Preparation of isolated rat liver cells. Methods Cell Biol. 13: 29-83.
17. Do, H., J. F. Healey, E. K. Waller, and P. Lollar. 1999. Expression of factor VIII by murine liver sinusoidal endothelial cells. J. Biol. Chem. 274: 19587-19592.
18. Federico, L., H. Ren, P. A. Mueller, T. Wu, S. Liu, J. Popovic, E. M. Blalock, M. Sunkara, H. Ovaa, H. M. Albers, et al. 2012. Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice. Mol. Endocrinol. 26: 786-797.
19. Hausmann, J., S. Kamtekar, E. Christodoulou, J. E. Day, T. Wu, Z. Fulkerson, H. M. Albers, L. A. van Meeteren, A. J. Houben, L. van Zeijl, et al. 2011. Structural basis of substrate discrimination and integrin binding by autotaxin. Nat. Struct. Mol. Biol. 18: 198-204.
20. Fulkerson, Z., T. Wu, M. Sunkara, C. V. Kooi, A. J. Morris, and S. S. Smyth. 2011. Binding of autotaxin to integrins localizes lysophosphatidic acid production to platelets and mammalian cells. J. Biol. Chem. 286: 34654-34663.
21. Selim, S., M. Sunkara, A. K. Salous, S. W. Leung, E. V. Berdyshev, A. Bailey, C. L. Campbell, R. Charnigo, A. J. Morris, and S. S. Smyth. 2011. Plasma levels of sphingosine 1-phosphate are strongly correlated with haematocrit, but variably restored by red blood cell transfusions. Clin. Sci. (Lond.). 121: 565-572.
22. Gellett, A. M., Y. Kharel, M. Sunkara, A. J. Morris, and K. R. Lynch. 2012. Biosynthesis of alkyl lysophosphatidic acid by diacylglycerol kinases. Biochem. Biophys. Res. Commun. 422: 758-763.
23. Sugiura, T., S. Nakane, S. Kishimoto, K. Waku, Y. Yoshioka, A. Tokumura, and D. J. Hanahan. 1999. Occurrence of lysophosphatidic acid and its alkyl ether-linked analog in rat brain and comparison of their biological activities toward cultured neural cells. Biochim. Biophys. Acta. 1440: 194-204.
24. Nakane, S., A. Tokumura, K. Waku, and T. Sugiura. 2001. Hen egg yolk and white contain high amounts of lysophosphatidic acids, growth factor-like lipids: distinct molecular species compositions. Lipids. 36: 413-419.
25. Morris, C. J. 1944. The determination of plasma volume by the Evans blue method: the analysis of haemolysed plasma. J. Physiol. 102: 441-445.
26. Smyth, S. S., V. A. Sciorra, Y. J. Sigal, Z. Pamuklar, Z. Wang, Y. Xu, G. D. Prestwich, and A. J. Morris. 2003. Lipid phosphate phosphatases regulate lysophosphatidic acid production and signaling in platelets: studies using chemical inhibitors of lipid phosphate phosphatase activity. J. Biol. Chem. 278: 43214-43223.
27. Jiang, G., Y. Xu, Y. Fujiwara, T. Tsukahara, R. Tsukahara, J. Gajewiak, G. Tigyi, and G. D. Prestwich. 2007. Alpha-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA. ChemMedChem. 2: 679-690.
28. Zhang, H., X. Xu, J. Gajewiak, R. Tsukahara, Y. Fujiwara, J. Liu, J. I. Fells, D. Perygin, A. L. Parrill, G. Tigyi, et al. 2009. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res. 69: 5441-5449.
29. Lynch, K. R., and T. L. Macdonald. 2002. Structure-activity relationships of lysophosphatidic acid analogs. Biochim. Biophys. Acta. 1582: 289-294.
30. East, J. E., A. J. Kennedy, J. L. Tomsig, A. R. De Leon, K. R. Lynch, and T. L. Macdonald. 2010. Synthesis and structure-activity relationships of tyrosine-based inhibitors of autotaxin (ATX). Bioorg. Med. Chem. Lett. 20: 7132-7136.
31. Shen, Z., M. Wu, P. Elson, A. W. Kennedy, J. Belinson, G. Casey, and Y. Xu. 2001. Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases. Gynecol. Oncol. 83: 25-30.
32. van der Bend, R. L., J. de Widt, E. J. van Corven, W. H. Moolenaar, and W. J. van Blitterswijk. 1992. Metabolic conversion of the biologically active phospholipid, lysophosphatidic acid, in fibroblasts. Biochim. Biophys. Acta. 1125: 110-112.
33. McIntyre, T. M., A. V. Pontsler, A. R. Silva, A. St Hilaire, Y. Xu, J. C. Hinshaw, G. A. Zimmerman, K. Hama, J. Aoki, H. Arai, et al. 2003. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc. Natl. Acad. Sci. USA. 100: 131-136.
34. Hanel, P., P. Andreani, and M. H. Graler. 2007. Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB J. 21: 1202-1209.
35. Kim, R. H., K. Takabe, S. Milstien, and S. Spiegel. 2009. Export and functions of sphingosine-1-phosphate. Biochim. Biophys. Acta. 1791: 692-696.
36. Watanabe, N., H. Ikeda, K. Nakamura, R. Ohkawa, Y. Kume, T. Tomiya, K. Tejima, T. Nishikawa, M. Arai, M. Yanase, et al. 2007. Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity. Life Sci. 81: 1009-1015.
37. Watanabe, N., H. Ikeda, K. Nakamura, R. Ohkawa, Y. Kume, J. Aoki, K. Hama, S. Okudaira, M. Tanaka, T. Tomiya, et al. 2007. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J. Clin. Gastroenterol. 41: 616-623.
38. Kremer, A. E., J. J. Martens, W. Kulik, F. Rueff, E. M. Kuiper, H. R. van Buuren, K. J. van Erpecum, J. Kondrackiene, J. Prieto, C. Rust, et al. 2010. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology. 139: 1008-1018, 1018. e1.
39. Tigyi, G. 2010. Aiming drug discovery at lysophosphatidic acid targets. Br. J. Pharmacol. 161: 241-270.